Cargando…

Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity

Lung adenocarcinoma (LUAD) is a common type of malignant tumor with poor prognosis and high mortality. In our previous studies, we found that estrogen is an important risk factor for LUAD, and different estrogen statuses can predict different prognoses. Therefore, in this study, we constructed a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yangwei, Yu, Tong, Chen, Jiaping, Zhao, Rong, Diao, Mingxin, Mei, Peiyuan, He, Shiwen, Qiu, Wenlin, Ye, Guanchao, Jiang, Lijuan, Xiao, Han, Liao, Yongde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619241/
https://www.ncbi.nlm.nih.gov/pubmed/37907850
http://dx.doi.org/10.1186/s12885-023-11415-y
_version_ 1785129944453480448
author Wang, Yangwei
Yu, Tong
Chen, Jiaping
Zhao, Rong
Diao, Mingxin
Mei, Peiyuan
He, Shiwen
Qiu, Wenlin
Ye, Guanchao
Jiang, Lijuan
Xiao, Han
Liao, Yongde
author_facet Wang, Yangwei
Yu, Tong
Chen, Jiaping
Zhao, Rong
Diao, Mingxin
Mei, Peiyuan
He, Shiwen
Qiu, Wenlin
Ye, Guanchao
Jiang, Lijuan
Xiao, Han
Liao, Yongde
author_sort Wang, Yangwei
collection PubMed
description Lung adenocarcinoma (LUAD) is a common type of malignant tumor with poor prognosis and high mortality. In our previous studies, we found that estrogen is an important risk factor for LUAD, and different estrogen statuses can predict different prognoses. Therefore, in this study, we constructed a prognostic signature related to estrogen reactivity to determine the relationship between different estrogen reactivities and prognosis. We downloaded the LUAD dataset from The Cancer Genome Atlas (TCGA) database, calculated the estrogen reactivity of each sample, and divided them into a high-estrogen reactivity group and a low-estrogen reactivity group. The difference in overall survival between the groups was significant. We also analyzed the status of immune cell infiltration and immune checkpoint expression between the groups. We analyzed the differential gene expression between the groups and screened four key prognostic factors by the least absolute shrinkage and selection operator (LASSO) regression and univariable and multivariable Cox regression. Based on the four genes, a risk signature was established. To a certain extent, the receiver operating characteristic (ROC) curve showed the predictive ability of the risk signature, which was further verified using the GSE31210 dataset. We also determined the role of estrogen in LUAD using an orthotopic mouse model. Additionally, we developed a predictive nomogram combining the risk signature with other clinical characteristics. In conclusion, our four-gene prognostic signature based on estrogen reactivity had prognostic value and can provide new insights into the development of treatment strategies for LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11415-y.
format Online
Article
Text
id pubmed-10619241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106192412023-11-02 Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity Wang, Yangwei Yu, Tong Chen, Jiaping Zhao, Rong Diao, Mingxin Mei, Peiyuan He, Shiwen Qiu, Wenlin Ye, Guanchao Jiang, Lijuan Xiao, Han Liao, Yongde BMC Cancer Research Lung adenocarcinoma (LUAD) is a common type of malignant tumor with poor prognosis and high mortality. In our previous studies, we found that estrogen is an important risk factor for LUAD, and different estrogen statuses can predict different prognoses. Therefore, in this study, we constructed a prognostic signature related to estrogen reactivity to determine the relationship between different estrogen reactivities and prognosis. We downloaded the LUAD dataset from The Cancer Genome Atlas (TCGA) database, calculated the estrogen reactivity of each sample, and divided them into a high-estrogen reactivity group and a low-estrogen reactivity group. The difference in overall survival between the groups was significant. We also analyzed the status of immune cell infiltration and immune checkpoint expression between the groups. We analyzed the differential gene expression between the groups and screened four key prognostic factors by the least absolute shrinkage and selection operator (LASSO) regression and univariable and multivariable Cox regression. Based on the four genes, a risk signature was established. To a certain extent, the receiver operating characteristic (ROC) curve showed the predictive ability of the risk signature, which was further verified using the GSE31210 dataset. We also determined the role of estrogen in LUAD using an orthotopic mouse model. Additionally, we developed a predictive nomogram combining the risk signature with other clinical characteristics. In conclusion, our four-gene prognostic signature based on estrogen reactivity had prognostic value and can provide new insights into the development of treatment strategies for LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11415-y. BioMed Central 2023-10-31 /pmc/articles/PMC10619241/ /pubmed/37907850 http://dx.doi.org/10.1186/s12885-023-11415-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Yangwei
Yu, Tong
Chen, Jiaping
Zhao, Rong
Diao, Mingxin
Mei, Peiyuan
He, Shiwen
Qiu, Wenlin
Ye, Guanchao
Jiang, Lijuan
Xiao, Han
Liao, Yongde
Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title_full Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title_fullStr Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title_full_unstemmed Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title_short Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
title_sort immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619241/
https://www.ncbi.nlm.nih.gov/pubmed/37907850
http://dx.doi.org/10.1186/s12885-023-11415-y
work_keys_str_mv AT wangyangwei immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT yutong immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT chenjiaping immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT zhaorong immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT diaomingxin immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT meipeiyuan immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT heshiwen immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT qiuwenlin immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT yeguanchao immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT jianglijuan immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT xiaohan immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity
AT liaoyongde immunecharacteristicsanalysisandconstructionofafourgeneprognosticsignatureforlungadenocarcinomabasedonestrogenreactivity